Drug Profile


Alternative Names: LY-2484595

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antihyperlipidaemics; Benzazepines; Carboxylic acids; Cyclohexanes; Small molecules; Tetrazoles
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia; Hyperlipidaemia
  • Phase I Cardiovascular disorders
  • No development reported Atherosclerosis

Most Recent Events

  • 30 Aug 2017 Efficacy data from the phase III ACCELERATE trial in Cardiovascular disorders presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2017)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Sep 2016 Eli Lilly terminates the phase III ACCENTUATE trial in Hyperlipidaemia (Adjunctive treatment) in USA and Puerto Rico (PO) due to insufficient efficacy (NCT02227784)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top